Ronald A. Rader

Latest from Ronald A. Rader

Total Global Capacity Finally Shows Improved Productivity
Economics
Total Global Capacity Finally Shows Improved ProductivityTotal Global Capacity Finally Shows Improved Productivity
byEric S. Langer, Ronald A. Rader
May 21, 2021
Top Trends in Biomanufacturing
Economics
Top Trends in BiomanufacturingTop Trends in Biomanufacturing
byRonald A. Rader
Feb 4, 2021

All from Ronald A. Rader

Biosimilars Pipeline and Market Trends
Biosimilars
Biosimilars Pipeline and Market Trends
Biosimilars Pipeline and Market Trends
Jun 12, 2020
byRonald A. Rader
Worldwide Biopharmaceutical CMO Capacity Analysis
Contract Services
Worldwide Biopharmaceutical CMO Capacity Analysis
Worldwide Biopharmaceutical CMO Capacity Analysis
Feb 14, 2019
byRonald A. Rader, Eric S. Langer
Worldwide Biopharmaceutical Manufacturing Capacity Analysis: Growth Continues Across the Board
Economics
Worldwide Biopharmaceutical Manufacturing Capacity Analysis: Growth Continues Across the Board
Worldwide Biopharmaceutical Manufacturing Capacity Analysis: Growth Continues Across the Board
Sep 15, 2018
byRonald A. Rader, Eric S. Langer
eBook: The Commercial Expression Systems Market — What Has Changed in the Past Decade
Expression Platforms
eBook: The Commercial Expression Systems Market — What Has Changed in the Past Decade
eBook: The Commercial Expression Systems Market — What Has Changed in the Past Decade
May 3, 2018
byRonald A. Rader
Biosimilar Markets and Regulation: Which Countries Are Going All In? logo in a gray background | Biosimilar Markets and Regulation: Which Countries Are Going All In?
Biosimilars
Biosimilar Markets and Regulation: Which Countries Are Going All In?
Biosimilar Markets and Regulation: Which Countries Are Going All In?
Apr 12, 2017
byRonald A. Rader
Future Manufacturing Strategies for Biosimilars
Biosimilars
Future Manufacturing Strategies for Biosimilars
Future Manufacturing Strategies for Biosimilars
May 17, 2016
byRonald A. Rader, Eric S. Langer
30 Years of Upstream Productivity Improvements
Expression Platforms
30 Years of Upstream Productivity Improvements
30 Years of Upstream Productivity Improvements
Feb 6, 2015
byRonald A. Rader, Eric S. Langer
Bioprocessing Challenges of Antibody–Drug Conjugates
MAb
Bioprocessing Challenges of Antibody–Drug Conjugates
Bioprocessing Challenges of Antibody–Drug Conjugates
Oct 15, 2014
byRonald A. Rader
A Novel Solid-Media <i>E. coli</i> Platform: Comparison with Standard Fermentation Processes
Cell Culture Media
A Novel Solid-Media E. coli Platform: Comparison with Standard Fermentation Processes
A Novel Solid-Media E. coli Platform: Comparison with Standard Fermentation Processes
Sep 11, 2014
+1
byVinod Pandiripally, Jeremy Leeand 1 more
Powders and Bulk Liquids logo in a gray background | Powders and Bulk Liquids
Biochemicals/Raw Materials
Powders and Bulk Liquids
Powders and Bulk Liquids
Mar 1, 2014
byEric S. Langer, Ronald A. Rader
Bioprocess Advances Drive Vaccine Manufacturing in Developing Countries logo in a gray background | Bioprocess Advances Drive Vaccine Manufacturing in Developing Countries
MAb
Bioprocess Advances Drive Vaccine Manufacturing in Developing Countries
Bioprocess Advances Drive Vaccine Manufacturing in Developing Countries
Feb 1, 2014
byRonald A. Rader, Eric S. Langer
An Analysis of the US Biosimilars Development Pipeline and Likely Market Evolution logo in a gray background | An Analysis of the US Biosimilars Development Pipeline and Likely Market Evolution
Biosimilars
An Analysis of the US Biosimilars Development Pipeline and Likely Market Evolution
An Analysis of the US Biosimilars Development Pipeline and Likely Market Evolution
Jun 1, 2013
byRonald A. Rader
<p> FDA Biopharmaceutical Product Approvals and Trends in 2012 </p> logo in a gray background | <p> FDA Biopharmaceutical Product Approvals and Trends in 2012 </p>
MAb
FDA Biopharmaceutical Product Approvals and Trends in 2012
FDA Biopharmaceutical Product Approvals and Trends in 2012
Mar 1, 2013
byRonald A. Rader
Upstream Single-Use Bioprocessing Systems logo in a gray background | Upstream Single-Use Bioprocessing Systems
Single Use
Upstream Single-Use Bioprocessing Systems
Upstream Single-Use Bioprocessing Systems
Feb 1, 2012
byRonald A. Rader, Eric S. Langer
<p> Nomenclature of New Biosimilars Will Be Highly Controversial </p> logo in a gray background | <p> Nomenclature of New Biosimilars Will Be Highly Controversial </p>
Biosimilars
Nomenclature of New Biosimilars Will Be Highly Controversial
Nomenclature of New Biosimilars Will Be Highly Controversial
Jun 1, 2011
byRonald A. Rader

Webinars

Ask the Expert webcasts
ATE Webcasts
Register Now: Demonstrating a Modular Selectivity With a Weak AEX-HIC Resin for Achieving High mAb Purity and Recovery in a Downstream Process
Register Now: Demonstrating a Modular Selectivity With a Weak AEX-HIC Resin for Achieving High mAb Purity and Recovery in a Downstream Process
Insider News
See all
Jun 5 - Jun 6, 2024
Exploit Advances in Exosomes to Improve Efficiencies in Drug Delivery: Connect with senior-level executives and scientists who will share new data and novel case studies on advancing EV products through clinical stage towards commercialization
Learn More

Innovative Technology

Thermo Fisher Scientific peptones white paper
Sponsored Content
The Value of Peptones for Enhancing Biopharmaceutical Productivity
The Value of Peptones for Enhancing Biopharmaceutical Productivity

Jan 27, 2025

Nagase Trehalose SG
Sponsored Content
Innovative Impurity Reduction in Harvesting Process With TREHALOSE SG
Innovative Impurity Reduction in Harvesting Process With TREHALOSE SG

Jan 9, 2025

Bruker Tornado Spectroscopy
Sponsored Content
Monitoring and Controlling Upstream Bioprocesses with Raman Spectroscopy
Monitoring and Controlling Upstream Bioprocesses with Raman Spectroscopy

Dec 1, 2024

Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.
Subscribe